BioXcel Therapeutics (BTAI) Tops Q2 EPS by 50c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q2 EPS of ($0.21), $0.50 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $1.1 million versus the consensus estimate of $662.5 thousand.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
• General Electric wins $2.9B Navy engine contract from DoD
• Cascadero Copper to sell subsidiary to Lumina Copper for up to $19M